Monthly Injectable Buprenorphine Cuts Healthcare Costs by 42%, Study Finds

A new real-world study published in Frontiers in Public Health reveals that patients who stay adherent to monthly injectable buprenorphine treatment experience dramatically lower healthcare costs and use fewer emergency services compared to those using other medications for opioid use disorder.

The research, released March 11, 2026 by Indivior Pharmaceuticals, analyzed claims data from commercially insured patients and found those adherent to SUBLOCADE—an extended-release buprenorphine injection—over 12 months had annual non-medication medical costs of $35,761, compared to $50,778 for patients using other forms of medication-assisted treatment. That $15,017 difference represents a 42% reduction in healthcare spending.

Beyond the cost savings, patients receiving the monthly injection had the lowest rates of hospitalizations, emergency department visits, and detoxification services across all treatment groups studied. The findings add weight to a growing body of evidence suggesting long-acting injectable treatments help patients stay engaged with care while reducing reliance on acute, high-cost medical interventions.

Following Patients Through Real-World Treatment

The retrospective observational study divided patients into three groups based on their medication adherence patterns during a 12-month follow-up period: those who stayed adherent to SUBLOCADE injections, those who were adherent to other medications for opioid use disorder like transmucosal buprenorphine tablets or films, and those who were not adherent to any medication treatment.

Researchers tracked healthcare utilization and costs using administrative claims from a commercial insurance database. The study population consisted of adults diagnosed with opioid use disorder who had initiated medication treatment. Patients adherent to the monthly injectable consistently showed better outcomes across nearly every metric measured.

Dr. Christian Heidbreder, Chief Scientific Officer at Indivior, emphasized the clinical implications: "These data highlight the potential of long-acting injectable buprenorphine treatment to improve care continuity for people living with OUD and reduce the need for acute, high-cost healthcare services."

Why Monthly Injections May Drive Better Adherence

The difference in outcomes likely reflects several factors unique to long-acting injectable formulations. Unlike daily oral medications that require patients to remember doses every morning, monthly injections administered by a healthcare provider eliminate the day-to-day adherence burden. Patients visit a clinic once every four weeks for their injection, creating regular touchpoints with the treatment system.

This built-in structure may help explain the reduction in crisis-driven care. When treatment continuity breaks down—whether from missed doses, loss of prescription access, or other disruptions—patients face heightened overdose risk and often end up in emergency departments or requiring inpatient detoxification. The monthly injection model appears to buffer against those gaps.

The study also found that patients not adherent to any medication had lower overall medical costs than those using other forms of treatment, but researchers caution this reflects disengagement from care rather than better health outcomes. These individuals likely rely on emergency services during acute crises but avoid routine outpatient care, a pattern that often precedes serious medical events or fatal overdoses.

Implementation Challenges Remain

Despite the promising cost and utilization findings, the study's authors acknowledge medication adherence rates remain low across all forms of opioid use disorder treatment. Only a fraction of patients with OUD receive medication at all, and among those who do, many discontinue treatment within months.

Patrick Barry, Chief Commercial Officer at Indivior, argued the findings should shift how healthcare systems evaluate treatment options: "These findings reinforce the importance of evaluating OUD treatment based on total healthcare cost. Sustained engagement with long-acting therapy can reduce costly acute care use, generating meaningful system-wide savings while supporting treatment continuity for patients."

Insurance coverage for long-acting injectables varies widely, and prior authorization requirements can create access barriers. The monthly cost of SUBLOCADE typically exceeds that of generic buprenorphine tablets, though the study suggests those upfront medication costs may be offset by reductions in hospitalizations and emergency visits. Whether payers and healthcare systems will incorporate these total-cost-of-care analyses into coverage decisions remains an open question.

The study has several limitations. As a retrospective analysis of claims data, it cannot establish causation—only associations between treatment type and outcomes. Coding errors in administrative databases may affect accuracy, and unmeasured factors like patient motivation or social support could confound the results. Additionally, portions of the study period overlapped with the COVID-19 pandemic, when healthcare utilization patterns were disrupted nationwide.

At the time the research was conducted, SUBLOCADE was the only extended-release buprenorphine injection available in the U.S. market, so the findings specifically reflect that product's real-world performance.

Broader Context: A Treatment System Struggling With Capacity

The study emerges amid a national overdose crisis that has claimed hundreds of thousands of lives over the past decade. While preliminary data from late 2025 showed encouraging declines in fatal overdoses, approximately 48.5 million Americans met criteria for a substance use disorder in 2024—yet fewer than one in ten received any form of treatment.

Medication for opioid use disorder, including buprenorphine, methadone, and naltrexone, remains the most evidence-based intervention available. Studies consistently show these medications cut overdose risk by half or more. However, treatment deserts persist across much of the country, particularly in rural areas where providers with prescribing waivers and clinic capacity are scarce.

The federal government eliminated the X-waiver requirement for buprenorphine prescribing in 2023, theoretically allowing any clinician with a DEA license to prescribe the medication. Yet uptake has been slow, and many primary care physicians remain hesitant to treat opioid use disorder due to lack of training, reimbursement concerns, or stigma.

Long-acting injectables like SUBLOCADE require a clinical setting for administration, which means they depend on infrastructure—trained staff, clinic space, supply chain access—that doesn't exist everywhere. The medication must be stored under specific conditions and administered by someone familiar with subcutaneous injection technique. For healthcare systems operating on thin margins, adding this service line involves upfront investment and operational complexity.

On the other hand, monthly injections may help retain patients who struggle with the logistics of daily oral medication—particularly those experiencing housing instability, complex work schedules, or chaotic life circumstances that make routine pill-taking difficult. For some patients, knowing they're "covered" for a full month after a single clinic visit removes a significant source of stress and relapse risk.

What Comes Next

The Frontiers in Public Health study contributes to an evolving conversation about how to structure opioid use disorder treatment in ways that maximize both clinical effectiveness and economic sustainability. As healthcare systems face pressure to manage costs while improving outcomes, evidence showing that higher-adherence treatment modalities generate downstream savings may influence formulary decisions and coverage policies.

Additional research is needed to understand which patients benefit most from long-acting injectable formulations versus other treatment approaches. Opioid use disorder is not a monolithic condition—people differ in their treatment preferences, co-occurring mental health needs, social circumstances, and prior treatment experiences. Some may thrive with the autonomy of at-home oral medication, while others may need the structure of supervised monthly injections. Ideally, treatment systems would offer both, allowing clinicians and patients to match approach to individual needs.

The study reinforces a central principle of addiction medicine that often gets lost in policy debates: continuity of care matters. Whether through long-acting injectables, telehealth buprenorphine, methadone clinics, or other modalities, keeping people engaged with treatment saves lives and reduces the costly, traumatic cycle of relapse and crisis.

The challenge, as always, is translating evidence into practice—ensuring that the treatments proven to work actually reach the people who need them.